NEWSROOM | Galderma

Galderma launches advanced new serum with ALASTIN Skincare® - C-RADICAL Defense Antioxidant Serum

Galderma launches advanced new serum with ALASTIN Skincare® - C-RADICAL Defense Antioxidant Serum

Powered by Peptides: Galderma introduces Cetaphil Healthy Renew, a retinol alternative skincare range

Galderma reiterates its commitment to commercialize and continue developing the broadest Injectable Aesthetics portfolio on the market, following Ipsen's recent announcement

Galderma achieves record 2 B USD net sales for a six-month period in H1 2023, as it continues to demonstrate leading execution and innovation capabilities in dermatology

Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4

WCD 2023: Galderma’s scientific presentations

WCD 2023: Galderma to present extensive data demonstrating enduring commitment to delivering innovative solutions in dermatology

Galderma raises approximately USD 1 billion for newly issued shares in a private placement round

Galderma receives FDA approval for its newest hyaluronic acid filler, Restylane® Eyelight™

Acne awareness month 2023: driving education with acne answered

Galderma receives FDA approval for Sculptra® for cheek wrinkles

Augmented reality: patient experience trumps misconceptions around injectables